N-((R)-cyano-methyl-methyl)-3-(5-{4-[(tetrahydropyran-4-ylamino)methyl]phenyl}isoxazol-3-yl)benzamide | 1262846-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-((R)-cyano-methyl-methyl)-3-(5-{4-[(tetrahydropyran-4-ylamino)methyl]phenyl}isoxazol-3-yl)benzamide
• 英文别名: (R)-N-(1-cyanoethyl)-3-(5-(4-((tetrahydro-2H-pyran-4-ylamino)methyl)phenyl)isoxazol-3-yl)benzamide；N-[(1R)-1-cyanoethyl]-3-[5-[4-[(oxan-4-ylamino)methyl]phenyl]-1,2-oxazol-3-yl]benzamide
• CAS: 1262846-48-9
• 化学式: C₂₅H₂₆N₄O₃
• 分子量: 430.506
• InChiKey: LSEXYAQECWMUPY-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氨基四氢吡喃 在 sodium tetrahydroborate 、 三乙胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-((R)-cyano-methyl-methyl)-3-(5-{4-[(tetrahydropyran-4-ylamino)methyl]phenyl}isoxazol-3-yl)benzamide
  参考文献：
  名称：

  3,5-Diarylazoles as novel and selective inhibitors of protein kinase D

  摘要：

  The synthesis and preliminary studies of the SAR of novel 3,5-diarylazole inhibitors of Protein Kinase D (PKD) are reported. Notably, optimized compounds in this class have been found to be active in cellular assays of phosphorylation-dependant HDAC5 nuclear export, orally bioavailable, and highly selective versus a panel of additional putative histone deacetylase (HDAC) kinases. Therefore these compounds could provide attractive tools for the further study of PKD / HDAC5 signaling. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.014

文献信息

• [EN] ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS<br/>[FR] ARYLPYRAZOLES ET ARYLISOXAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA PROTÉINE KINASE C (PKD)
  申请人：NOVARTIS AG

  公开号：WO2011009484A1

  公开（公告）日：2011-01-27

  The present invention provides novel organic compounds of formula (I) or (Ia): which may be inhibitors of a selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example PKD-1/2/3, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. The selectivity of which would depend on the structural variation thereof, and for treatment of a disorder or disease mediated by those selected AGC or calmodulin family kinases. These organic compounds can be used to treat various PKD associated states such as heart failure, colorectal cancer, regulation of cell growth, autoimmune disorders, or hyperproliferative skin disorders.

  本发明提供了化学式(I)或(Ia)的新型有机化合物：这些化合物可能是AGC或钙调素激酶家族中的一部分激酶的抑制剂，例如PKD-1/2/3，组蛋白去乙酰化酶（HDAC）磷酸化的抑制剂，或其他激酶的抑制剂。其选择性取决于其结构变化，用于治疗由这些选定的AGC或钙调素家族激酶介导的疾病或疾病。这些有机化合物可用于治疗各种PKD相关状态，如心力衰竭、结直肠癌、细胞生长调节、自身免疫性疾病或过度增生性皮肤疾病。
• [EN] TREATMENT<br/>[FR] TRAITEMENT
  申请人：IMP INNOVATIONS LTD

  公开号：WO2015193680A1

  公开（公告）日：2015-12-23

  The present invention provides a protein kinase D (PKD) inhibitor for use in a method of treating or preventing picornavirus infection. Any PKD inhibitor may be use in the present invention, but the PKD inhibitor is typically selected from the group consisting of a small molecule, a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA (miRNA), an antisense RNA, a ribozyme, a DNAzyme and a cDNA encoding an inactive mutant of PKD.
• 3,5-Diarylazoles as novel and selective inhibitors of protein kinase D
  作者：Gabriel G. Gamber、Erik Meredith、Qingming Zhu、Wanlin Yan、Chang Rao、Michael Capparelli、Robin Burgis、Istvan Enyedy、Ji-Hu Zhang、Nicolas Soldermann、Kimberley Beattie、Olga Rozhitskaya、Keith A. Koch、Nikos Pagratis、Vinayak Hosagrahara、Richard B. Vega、Timothy A. McKinsey、Lauren Monovich

  DOI：10.1016/j.bmcl.2011.01.014

  日期：2011.3

  The synthesis and preliminary studies of the SAR of novel 3,5-diarylazole inhibitors of Protein Kinase D (PKD) are reported. Notably, optimized compounds in this class have been found to be active in cellular assays of phosphorylation-dependant HDAC5 nuclear export, orally bioavailable, and highly selective versus a panel of additional putative histone deacetylase (HDAC) kinases. Therefore these compounds could provide attractive tools for the further study of PKD / HDAC5 signaling. (C) 2011 Elsevier Ltd. All rights reserved.